Information Provided By:
Fly News Breaks for November 10, 2015
JAZZ
Nov 10, 2015 | 09:46 EDT
Cowen Jazz Pharmaceuticals shares are weak on a Xyrem shortfall and concerns of a slowdown in franchise growth. Analyst Ken Cacciatore said this is already well known, and would focus on Xyrem's duration, not growth. Cacciatore expects a Xyrem settlement in the next 6-9 months, which should provide need clarity on duration, and U.S. Defibrotide approval in Q1. Cowen's analyst recommends adding to positions and reiterates its Outperform rating and $190 price target on shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ